Li Zhu

TL;DR: Three independent loci in the major histocompatibility complex, as well as a common deletion of CFHR1 and CFHR3 at chromosome 1q32 and a locus at chromosome 22q12 that each surpassed genome-wide significance, explain 4–7% of the disease variance and up to a tenfold variation in interindividual risk.

TL;DR: The authors demonstrated that the amount of EGF in the urine is just as useful, providing a biomarker that can be easily tracked over time without requiring invasive biopsies, and identified uEGF as an independent risk predictor of CKD progression.

TL;DR: The findings show that IgAN is associated with variants near genes involved in innate immunity and inflammation, with multiple associations in the major histocompatibility complex (MHC) region.

TL;DR: The findings suggest that genetic variants in CFH, CFHR3, and CFHR1 affect complement activation and thereby, predispose patients to develop IgAN.

TL;DR: Two risk alleles of HLA class II genes and three amino acid residues on positions 13 and 71 of the MHC-DRβ1 chain that may confer susceptibility to iMN by presenting T cell epitopes on PLA2R are identified.